These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38233610)

  • 1. Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023.
    Findlay J; Raro OHF; Poirel L; Nordmann P;
    Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):551-557. PubMed ID: 38233610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
    Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
    Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predominance of carbapenem-resistant Pseudomonas aeruginosa isolates carrying blaIMP and blaVIM metallo-β-lactamases in a major hospital in Costa Rica.
    Toval F; Guzmán-Marte A; Madriz V; Somogyi T; Rodríguez C; García F
    J Med Microbiol; 2015 Jan; 64(Pt 1):37-43. PubMed ID: 25355933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of NDM-1 in Metallo-Beta-Lactamase-Producing Strains of Pseudomonas aeruginosa isolates from a Tertiary Hospital in Southwest Nigeria.
    Onipede A; Odetoyin B; Ojo O; Adejobi A
    West Afr J Med; 2021 Nov; Vol. 38(11):1072-1079. PubMed ID: 34921543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.
    Diorio-Toth L; Irum S; Potter RF; Wallace MA; Arslan M; Munir T; Andleeb S; Burnham CD; Dantas G
    Microbiol Spectr; 2022 Jun; 10(3):e0076622. PubMed ID: 35638817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of VIM-2-, IMP-1- and NDM-1-producing multidrug-resistant Pseudomonas aeruginosa in Malaysia.
    Liew SM; Rajasekaram G; Puthucheary SD; Chua KH
    J Glob Antimicrob Resist; 2018 Jun; 13():271-273. PubMed ID: 29432937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical
    Babouee Flury B; Bösch A; Gisler V; Egli A; Seiffert SN; Nolte O; Findlay J
    Front Cell Infect Microbiol; 2023; 13():1098944. PubMed ID: 37180441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of blaIMP, and blaVIM gene carriage in metallo-β-lactamase-producing burn isolates of Pseudomonas aeruginosa in Tehran.
    Salimi F; Eftekhar F
    Turk J Med Sci; 2014; 44(3):511-4. PubMed ID: 25558658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of Metallo-β-Lactamase-Producing
    Kabic J; Fortunato G; Vaz-Moreira I; Kekic D; Jovicevic M; Pesovic J; Ranin L; Opavski N; Manaia CM; Gajic I
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.